All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

by Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A
Published 2015

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

by Wilder, Julius M., Jeffers, Lennox J., Ravendhran, Natarajan, Shiffman, Mitchell L., Poulos, John, Sulkowski, Mark S., Gitlin, Norman, Workowski, Kimberly, Zhu, Yanni, Yang, Jenny C., Pang, Phillip S., McHutchison, John G., Muir, Andrew J., Howell, Charles, Kowdley, Kris, Afdhal, Nezam, Reddy, K. Rajender
Published 2015